Sarilumab (Kevzara) demonstrates mixed efficacy results in ongoing COVID-19 trial of hospitalised patients with severe or critical respiratory illness secondary to COVID-19

Trial will now only allow critical patients to be enrolled to receive sarilumab 400mg (an interleukin-6 receptor antibody) or placebo, after failing to show a benefit in a wider group.